Madrigal Pharmaceuticals (FRA:YDO1) Institutional Ownership

: 51.33% (As of Today)

View and export this data going back to 2007. Start your Free Trial

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Madrigal Pharmaceuticals's institutional ownership is 51.33%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Madrigal Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Madrigal Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 84.21%.

Madrigal Pharmaceuticals Institutional Ownership Historical Data

The historical data trend for Madrigal Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Madrigal Pharmaceuticals Historical Data

The historical data trend for Madrigal Pharmaceuticals can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	43.81	43.67	43.26	57.44	53.29	53.60	54.79	55.14	53.65	51.33

Madrigal Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Madrigal Pharmaceuticals (FRA:YDO1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Madrigal Pharmaceuticals Inc (FRA:YDO1) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

MDGL:USA

Address

200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428

Website

http://www.madrigalpharma.com

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Madrigal Pharmaceuticals (FRA:YDO1) Headlines

No Headlines